Sugi Predict

Sugi Predict / Compounds / SCHEMBL20096500

SCHEMBL20096500

SCHEMBL20096500

COC(=O)c1cccc2c1CC1(CC2)CCN(c2cccc(C(F)(F)F)c2)C1=O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC11 Q96DB2 6/20 0.68
▸ KDR P35968 1/20 0.40
▸ LMNA P02545 3/20 0.39
▸ TSHR P16473 2/20 0.39
▸ TP53 P04637 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ CYP17A1 P05093 1/20 0.37
▸ USP30 Q70CQ3 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CFTR P13569 1/20 0.37
▸ NPY5R Q15761 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20096680 0.93 HDAC11 (0.78) HDAC11KDRLMNATSHRTP53
SCHEMBL20096891 0.91 HDAC11 (0.78) HDAC11CFTR
SCHEMBL20096499 0.90 HDAC11 (0.70) HDAC11TSHRMAPTCYP17A1USP30
SCHEMBL20096501 0.88 HDAC11 (0.86) HDAC11CYP17A1ALDH1A1NPY5R
SCHEMBL20096497 0.83 HDAC11 (0.66) HDAC11CFTR
SCHEMBL20096864 0.83 HDAC11 (0.56) HDAC11SMN1; SMN2POLBMEN1KMT2A
SCHEMBL29754216 0.83 HDAC11 (0.56) HDAC11SMN1; SMN2POLBMEN1KMT2A
SCHEMBL20096629 0.81 HDAC11 (1.00) HDAC11
SCHEMBL20096682 0.80 HDAC11 (1.00) HDAC11CYP17A1
SCHEMBL20096701 0.79 HDAC11 (0.79) HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11345672-B2 Methods using HDAC11 inhibitors VALO HEALTH, INC. (US) 2022-05-31 — — US disclosed
US-20190084946-A1 METHODS USING HDAC11 INHIBITORS Valo Health, LLC 2019-03-21 — — US disclosed
US-20190084945-A1 METHODS USING HDAC11 INHIBITORS VALO HEALTH, INC. 2019-03-21 — — US disclosed
US-20180127386-A1 METHODS USING HDAC11 INHIBITORS VALO EARLY DISCOVERY, INC. 2018-05-10 — — US disclosed
WO-2018075959-A1 METHODS USING HDAC11 INHIBITORS FORMA THERAPEUTICS, INC. (US) 2018-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345672-B2 Methods using HDAC11 inhibitors HDAC11, HDAC1, HDAC10 HDAC11 1/4885KDR 4499/4885LMNA 2556/4885
US-20180127386-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885KDR 4499/4885LMNA 2556/4885
US-20190084945-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885KDR 4499/4885LMNA 2556/4885
US-20190084946-A1 METHODS USING HDAC11 INHIBITORS HDAC11, HDAC1, HDAC10 HDAC11 1/4885KDR 4499/4885LMNA 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.